Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

Examining Dietary Influences Of Liver Disease
Diets high in protein and cholesterol are associated with a higher risk of hospitalization or death due to cirrhosis or liver cancer, while diets high in carbohydrates are associated with a lower risk. These findings are in the July issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience.
generic viagra online
California Official Details Proposed Health Care Cuts In Schwarzenegger's Budget Plan
California Department of Finance Chief Deputy Director Ana Matosantos on Tuesday discussed Gov. Arnold Schwarzenegger"s (R) plans to address the state budget deficit in part by cutting Medi-Cal spending and eliminating Healthy Families, the Sacramento Bee reports. Medi-Cal is California"s Medicaid program, and Healthy Families is the state"s version of CHIP. Matosantos spoke at a Joint Legislative Budget Committee hearing (Yamamura, Sacramento Bee, 5/27).The suggested cuts to health care programs are part of the governor"s proposal to address the state"s projected $24.3 billion budget deficit for fiscal year 2009-2010 (Wiegand, Sacramento Bee, 5/23). Schwarzenegger last week outlined two budget proposals to address the state"s budget problems. One of the proposals addressed the situation if California voters approved a set of special ballot measures intended to provide funds for FY 2009-2010 (Kaiser Daily Health Policy Report, 5/18). However, voters last week rejected five of the six measures on the May 19 statewide ballot, including three propositions that would have let the state use special accounts for mental health services and early childhood education (Yi/Buchanan, San Francisco Chronicle, 5/20). The state would have faced a $15.4 billion budget deficit if voters had approved the measures (Ellis/Schultz, Fresno Bee, 5/20). Schwarzenegger and legislative leaders were scheduled to begin closed door budget negotiations on Tuesday, and a small group of state senators and Assembly members will hold a series of public sessions on the budget on Wednesday (Bailey, Los Angeles Times, 5/20). Democrats scheduled a press conference for Tuesday to announce their timeline for passing a budget, and Republicans also are set to release their plans for advancing a budget agreement.The San Francisco Chronicle reports that California will not have sufficient cash on hand to make some payments by late summer if a budget agreement is not reached quickly (Wildermuth, San Francisco Chronicle, 5/20).
plastic surgery before after
News of the day
Fibromyalgia: Doctor Offers Unbiased Overview In New Book
As many as fifteen million American women suffer from a disabling medical condition known as fibromyalgia. In the medical community, sides have been drawn over whether fibromyalgia is a genuine syndrome or a catchall diagnosis based on vague clinical criteria. In The Fibromyalgia Controversy, M. Clement Hall, MD presents an unbiased overview of the fibromyalgia situation today and reviews the most up-to-date opinions and studies on this condition and its surrounding controversy.
Medical Devices

Calixa Therapeutics Announces Initiation Of Phase 2 Clinical Trial Of Its Antibiotic, CXA-101, In Patients With Complicated Urinary Tract Infections

Calixa Therapeutics Inc. today announced the initiation of a Phase 2 clinical trial of CXA-101 in patients with complicated urinary tract infections. CXA-101 is a new broad-spectrum, parenteral cephalosporin antibiotic with excellent in vitro and in vivo activity against Pseudomonas aeruginosa, including drug resistant isolates. Calixa is investigating CXA-101 as a potential treatment for serious bacterial infections in hospitalized patients. The multi-center, randomized study is anticipated to enroll approximately 120 patients and will compare the efficacy and safety of CXA-101 with the current standard of therapy. The primary efficacy endpoint for this study is microbiological outcome at the test-of-cure visit between six to nine days after the end of therapy. "The preclinical and Phase 1 results to date are very promising and indicate that CXA-101 is well tolerated and has broad-spectrum antibacterial coverage, including potent activity against increasingly resistant gram-negative pathogens such as Pseudomonas aeruginosa," said Dr. Ian Friedland, chief medical officer of Calixa. "We are going to present comprehensive preclinical and Phase 1 data at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in September and other medical conferences. This Phase 2 study will generate important information on the safety and effectiveness of CXA-101 in complicated urinary tract infections, which are usually caused by gram-negative pathogens". Eckard Weber, president and chief executive officer of Calixa and partner at the venture capital firm Domain Associates, LLC said, "With the continually increasing incidence of serious and life-threatening infections caused by resistant gram-negative bacteria and the paucity of new drugs in the pipeline to counter such resistance, we are working diligently to expedite the development of CXA-101. We are fully committed to providing patients and physicians with a much needed option for the treatment of life-threatening infections caused by gram-negative bacteria." About Calixa Therapeutics Calixa Therapeutics Inc. is a biopharmaceutical company committed to the development and commercialization of novel medicines for the treatment of infectious diseases. The company"s initial focus is on developing novel antibiotics for use in the hospital setting. Calixa Therapeutics, which is privately held, is headquartered in San Diego and has operations in the San Francisco Bay Area. Calixa Therapeutics Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009